Phibro shares soared nearly 18% after strong Q4 results beat estimates, driven by growth from the Zoetis MFA acquisition and solid full-year performance.
Latest Ratings for PAHC
DateFirmActionFromTo Jan 2022BarclaysUpgradesUnderweightEqual-Weight Nov 2021Morgan StanleyInitiates Coverage OnEqual-Weight Jul 2021BarclaysDowngradesEqual-WeightUnderweight